ArteraAI and GenesisCare Partner to Provide Precision Cancer Therapy to Patients with Localized Prostate Cancer In Australia
Patients treated at GenesisCare clinics in Australia can work with clinicians to access AI-based decision making tools as par [...]
ArteraAI Validates its Prognostic Model in Advanced Prostate Cancer
The model was successfully validated in Phase 3 STAMPEDE trials with stronger prognostic associations than individual clinica [...]
ArteraAI Announces First-Ever AI-Derived Biomarker for Predicting Androgen Deprivation Therapy (ADT) Benefit in Prostate Cancer
Data published in the NEJM Evidence shows promise for personalized use of short-term ADT in men with predominantly intermedia [...]
ArteraAI Presents New Data Validating AI-Derived Predictive Biomarker at 2023 ASCO Annual Meeting
The biomarker is the first to predict long-term ADT usage in men with high-risk localized prostate cancer SAN FRANCISCO--(BUS [...]
ArteraAI and American Cancer Society Announce New Relationship
With the shared mission to improve the lives of those touched by cancer, both parties collaborate in the fight against the di [...]
ArteraAI Launches with $90 Million in Funding to Personalize Cancer Therapy With Multimodal AI
Funding supports the distribution of Artera’s flagship test in prostate cancer, as well as further test development across ca [...]
ArteraAI Announces Positive Results Around Its Multimodal Artificial Intelligence (MMAI) Prognostic Biomarker
Validated across six phase III randomized trials, the biomarker demonstrated the ability to help enable personalized, shared [...]
Our science was presented at the 2023 ASCO Genitourinary Cancers Symposium in San Francisco from February 16-18.
Patient-Level Data Meta-Analysis of a Multi-Modal Artificial Intelligence (MMAI) Prognostic Biomarker in High-Risk Prostate C [...]